Impact ledger
Bristol-Myers Squibb Company (BMY): the developments shaping its investment case
Follow the evidence affecting Bristol-Myers Squibb Company's valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Bristol-Myers Squibb Company · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-21 · 3 reports
Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge
Channel: Direct financial performance and strategic execution validation.
Bullish· 3-12m
2026-09-21 · 5 reports
Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix
Channel: Direct financial performance and strategic execution. Strong growth in new therapies mitigates patent cliff concerns, improving long-term revenue visibility and earnings stability.
Bullish· 3-12m
2026-08-30
Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis Expiration
Channel: Direct impact on future revenue streams and profitability due to patent expiration and new drug commercialization efforts.
mixed· 1-5y
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-08-06 | multiple | Bullish | Target re-rates to bid premium until close. |
Event impact log
30 events mapped to BMY since 2026-08-27. Evidence through 2026-09-29.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-29 | Oncolytics Biotech Inc. Announces Publication of Pelareorep Data in Liver Cancer | Potential future collaboration or competition in immunotherapy for liver cancer. BMY's Opdivo is a leading immunotherapy. | watch | 3-12m | 0.10 |
| 2026-09-29 | Oncolytics Biotech Announces Publication of Pelareorep Data in Liver Cancer | Potential for future collaboration or competition in the immunotherapy space, specifically for liver cancer. | watch | 3-12m | 0.30 |
| 2026-09-26 | C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data | Potential future competition in the multiple myeloma market, impacting drugs like Pomalyst and Abecma. | watch | 3-12m | 0.20 |
| 2026-09-26 | C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS | Indirect competitive landscape implications in multiple myeloma. | watch | 3-12m | 0.20 |
| 2026-09-25 | Moleculin Biotech, Inc. Announces New Preclinical Data for Annamycin in Pancreatic Cancer at AACR | Similar to Moderna, BMY is a major player in immuno-oncology with drugs like Opdivo. Positive news about novel mechanisms to enhance immune responses in difficult cancers could indirectly support the broader immuno-oncology thesis, potentially benefiting companies with established or developing asse | watch | 3-12m | 0.20 |
| 2026-09-25 | Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine Discovery | Broader industry trend towards AI in drug discovery, potentially increasing R&D efficiency across the pharmaceutical sector, but also raising competitive stakes. | watch | 3-12m | 0.20 |
| 2026-09-24 | Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026 | Bristol Myers Squibb has a strategic collaboration and license agreement with Kyverna for miv-cel. Positive data increases the value of this partnership and potential future royalty streams. | Bullish | 3-12m | 0.30 |
| 2026-09-24 | HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026 | Increased competitive pressure in the NSCLC market. Bristol-Myers Squibb's Opdivo (nivolumab) is also a significant player in NSCLC, and new effective treatments could impact its market position. | Bearish | 3-12m | 0.35 |
| 2026-09-21 | Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix | Direct financial performance and strategic execution. Strong growth in new therapies mitigates patent cliff concerns, improving long-term revenue visibility and earnings stability. | Bullish | 3-12m | 0.80 |
| 2026-09-21 | Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge | Direct financial performance and strategic execution validation. | Bullish | 3-12m | 0.90 |
| 2026-09-21 | Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth | Direct financial performance and successful strategic execution of product portfolio transition. | Bullish | 1-3m | 0.80 |
| 2026-09-21 | Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surge | Strong Q2 earnings beat, significant growth in newer therapies (growth portfolio) mitigating patent cliff concerns, improved investor sentiment. | Bullish | 1-3m | 0.80 |
| 2026-09-21 | Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60% | Direct financial performance and strategic execution. | Bullish | 3-12m | 0.80 |
| 2026-09-21 | Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2 | Stronger-than-expected new product growth mitigating patent cliff concerns, improving revenue mix and future outlook. | Bullish | 1-3m | 0.80 |
| 2026-09-21 | Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surge | Direct financial performance and improved investor sentiment regarding future growth prospects. | Bullish | 3-12m | 0.80 |
| 2026-09-21 | Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 Revenue | Strong performance of new product portfolio mitigating patent cliff concerns, improving investor sentiment and future growth outlook. | Bullish | 1-3m | 0.80 |
| 2026-09-20 | Electra Therapeutics sets terms for $347M Nasdaq IPO under ticker ETRA | Indirect sentiment read-through for large pharmaceutical companies with active M&A strategies in oncology/immunology. IPO success or struggle can influence valuation benchmarks for potential acquisition targets. | mixed | 1-3m | 0.20 |
| 2026-09-14 | Immunocore Holdings plc Announces Achievement of Target Enrollment in Registrational TEBE-AM Trial | Indirect competitive pressure in melanoma treatment. Progress in a novel therapy like KIMMTRAK could influence the competitive landscape for existing or pipeline melanoma drugs. | watch | 3-12m | 0.20 |
| 2026-09-01 | Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials | Increased competition for existing and pipeline MS drugs, potential market share erosion. | Bearish | 1-5y | 0.40 |
| 2026-09-01 | Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial | Increased competition in the multiple sclerosis market. Potential market share erosion for existing MS drugs or pipeline assets. | Bearish | 1-5y | 0.50 |
| 2026-09-01 | Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis | Increased competition in the multiple sclerosis market from a potentially superior oral BTK inhibitor could erode market share for existing and pipeline MS therapies. | Bearish | 1-5y | 0.30 |
| 2026-08-30 | Cytokinetics Presents Positive Aficamten Phase Data at ESC Congress 2026 | Indirect competitive pressure. Positive data for a competitor's drug in a shared therapeutic area could potentially impact future market share or pricing power for BMY's cardiovascular assets, if any are directly competitive or in development. | watch | 3-12m | 0.30 |
| 2026-08-30 | Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis Expiration | Direct impact on future revenue streams and profitability due to patent expiration and new drug commercialization efforts. | mixed | 1-5y | 0.80 |
| 2026-08-30 | Cytokinetics Presents Aficamten Phase 3 Data at ESC Congress 2026 | Potential competitive pressure or partnership opportunities in the broader cardiovascular pharmaceutical market. | watch | 3-12m | 0.10 |
| 2026-08-30 | Cytokinetics Presents Positive Aficamten Phase 3 Data at ESC Congress 2026 | Potential competitive pressure in the broader cardiovascular market, particularly if aficamten expands its indications or gains significant market share. | watch | 3-12m | 0.30 |
| 2026-08-27 | FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor | Indirect competitive pressure in the oncology market, particularly for therapies targeting RAS-mutated cancers or those with broad applicability. Potential for future M&A or partnership interest in the RAS space. | watch | 3-12m | 0.20 |
| 2026-08-27 | Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch | Potential future partnership or acquisition target for larger pharmaceutical companies seeking to expand their regenerative medicine pipeline, especially if RYONCIL continues strong growth and rexlemestrocel-L shows positive Phase 3 results. | watch | 1-5y | 0.20 |
| 2026-08-27 | Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch | Potential future competition or partnership in regenerative medicine/cell therapy space | watch | 3-12m | 0.20 |
| 2026-08-27 | FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer | General increase in competitive intensity within the oncology market, particularly for difficult-to-treat cancers. While not directly competing with a specific BMY drug, it contributes to the evolving treatment landscape. | mixed | 3-12m | 0.20 |
| 2026-08-27 | Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial | Potential future competition in pain management or regenerative medicine, or partnership opportunities. | watch | 3-12m | 0.20 |
Continue this research
Build your Bristol-Myers Squibb Company investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the BMY entity page →